Merck: Abbisko Says Merck Exercised Option For Global Rights Of Pimicotinib
(RTTNews) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 million, under the licensing agreement signed in December 2023.
Read full article »
Merck is a New Jersey-based multinational biopharmaceutical company that develops and commercializes novel therapeutics and vaccines for the treatment of a range of diseases.
Read more